Reduced Vancomycin Susceptibility Tied to Poorer C. Diff Outcomes
By Lori Solomon HealthDay Reporter
TUESDAY, April 30, 2024 -- Reduced vancomycin susceptibility is impacting clinical responses among adults with Clostridioides difficile (C. difficile) infection, according to a study recently published in Clinical Infectious Diseases.
Taryn A. Eubank, Pharm.D., from the University of Houston College of Pharmacy, and colleagues examined if reduced vancomycin susceptibility is associated with decreased rates of sustained clinical response (SCR) among adults with C. difficile infection treated with oral vancomycin between 2016 and 2021.
The researchers found that 34 percent of C. difficile isolates showed reduced vancomycin susceptibility (range, 0.5 to 16 μg/mL; MIC50/90 = 2/4 μg/mL). The highest proportion (77.4 percent) of isolates with reduced vancomycin susceptibility were ribotype 027. Overall, 30-day SCR was achieved by 83 percent of patients. There was an association between reduced vancomycin susceptibility and lower rates of 30-day SCR (76 percent) versus vancomycin-susceptible strains (86 percent). Similarly, the 14-day initial cure rate was significantly lower among individuals infected with strains with reduced vancomycin susceptibility (89 versus 96 percent). In multivariable modeling, reduced susceptibility remained an independent predictor of 30-day SCR (odds ratio, 0.52).
"It's an alarming development in the field of C. diff as there are only two recommended antibiotics," coauthor Kevin Garey, Pharm.D., also from the University of Houston, said in a statement. "If antimicrobial resistance increases in both antibiotics, it will complicate the management of C. diff infection leading us back to a pre-antibiotic era."
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
AGA Recommends Fecal Microbiota Transplant for Recurrent C. Difficile
MONDAY, Feb. 26, 2024 -- Fecal microbiota transplant is recommended on completion of standard-of-care antibiotics to prevent recurrence for adults with recurrent Clostridioides...
Doxycycline Tied to Lower Risk for C. Difficile in Pneumonia Patients
THURSDAY, Nov. 30, 2023 -- For patients with community-acquired pneumonia (CAP), doxycycline is associated with a reduced risk for Clostridioides difficile infection (CDI)...
Guidance Provided for Fecal Microbiota Transplantation in Children
MONDAY, Nov. 20, 2023 -- For pediatric patients, fecal microbiota transplantation (FMT) is recommended for moderate-to-severe or recurrent Clostridioides difficile infection...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.